
NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA



Press Release

Zug, 11 March 2011

Closing of the sale of PharmaSwiss to Valeant

The sale of PharmaSwiss SA to Valeant Pharmaceuticals International, Inc. was closed yesterday. With the closing, HBM BioVentures received net sale proceeds of EUR 93 million, which have been converted into CHF 120 million. A further EUR 2.9 / CHF 3.7 million are held in escrow. In total HBM has realized a profit of EUR 41.9 million on its investment in PharmaSwiss.

For further information, please contact Dr. Andreas Wicki, CEO HBM BioVentures Ltd, Tel.: +41 41 768 11 08, andreas.wicki@hbmbioventures.com.

About HBM BioVentures Ltd

As a venture capital company, HBM BioVentures is invested globally in some 30 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The lead products of many companies in HBM BioVentures' portfolio are either at an advanced stage of development or already available on the market. The Company focuses on unlisted emerging companies, with two-thirds of assets being invested in private companies that offer high value-creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN). Visit www.hbmbioventures.com.

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (Wertpapierprospektgesetz). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requierments of US securities legislation.